Literature DB >> 28732566

Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents.

Han Byul Jang1, Hyo-Jin Kim1, Jae Heon Kang2, Sang Ick Park1, Kyung Hee Park3, Hye-Ja Lee4.   

Abstract

CONTEXT: Irisin, a novel exercise-induced myokine, has been suggested to regulate energy metabolism.
OBJECTIVE: We studied the relationship between circulating irisin and metabolic and metabolite profiles of Korean adolescents, and investigated the effects of physical activity, obesity, and metabolic syndrome (MetS) on irisin levels.
MATERIALS AND METHODS: Data were obtained from the Korean Children-Adolescents Study. Our cross-sectional study included 618 adolescents (370 normal-weight and 248 obese adolescents; 316 boys and 302 girls) aged 12-15years. Body composition was determined using an impedance body composition analyzer and general participant characteristics and lifestyle information were obtained from questionnaires. Serum irisin levels were measured using a commercial kit.
RESULTS: Mean body mass index (BMI) was 19.4kg/m2 in normal-weight adolescents and 31.4kg/m2 in obese adolescents. Circulating irisin was positively correlated with adiposity indices, including BMI z-score, waist circumference, percent body fat, fat mass, fat-free mass, fat mass to fat-free mass ratio, and lipid and glucose metabolism markers, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, glucose, insulin, and homeostasis model assessment-estimated insulin resistance (all p≤0.006). Of these, increased body fat mass [standardized (Std) ß, 0.23; p<0.0001], LDL-C (Std ß, 0.14; p=0.0005) and fasting glucose (Std ß, 0.08; p=0.0383) were the main independent factors associated with higher irisin levels. Moreover, elevated serum irisin was associated with the risk of obesity [odds ratio (OR], 2.2; confidence interval (CI), 1.19-3.87] and MetS (OR, 2.0; CI, 1.15-3.47). Furthermore, irisin and branched-chain amino acids were positively associated (p<4×10-4 for Bonferroni correction). Additionally, in the normal-weight group, girls had higher irisin levels than boys (p=0.006) and adolescents who engaged in regular physical activity had higher levels of irisin than sedentary adolescents (p=0.0388). The relationship between physical activity and irisin levels was not observed in obese adolescents.
CONCLUSIONS: Elevated serum irisin was independently associated with the risk of obesity and positively correlated with unhealthy metabolic parameters and metabolites. Moreover, irisin levels were higher in active versus sedentary adolescents in the normal-weight group, but not in the obese group. Our findings suggest that irisin plays an important role in metabolic disorders and may be affected by physiopathological status.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; Fat mass; Irisin; Metabolite; Obesity

Mesh:

Substances:

Year:  2017        PMID: 28732566     DOI: 10.1016/j.metabol.2017.05.007

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  25 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  INFLUENCE OF GLYCEMIC CONTROL AND BODY COMPOSITION ON IRISIN LEVELS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS.

Authors:  S E Beray; M E Atabek; Y Kücükkagnici; S Kurban; M B Selver; M S Iyisoy
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

3.  Circulating Irisin in Children and Adolescents With Prader-Willi Syndrome: Relation With Glucose Metabolism.

Authors:  Stefania Mai; Danilo Fintini; Chiara Mele; Alessio Convertino; Sarah Bocchini; Graziano Grugni; Gianluca Aimaretti; Roberta Vietti; Massimo Scacchi; Antonino Crinò; Paolo Marzullo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-14       Impact factor: 6.055

4.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

5.  Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis.

Authors:  Yan Li; Zhenbin Xu
Journal:  Diabetol Metab Syndr       Date:  2022-10-21       Impact factor: 5.395

6.  Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Jian-Lei Cao; Qiang Liu; Xian-Wei Zeng; Ji-Zong Zhao
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

7.  Serum irisin associates with breast cancer to spinal metastasis.

Authors:  Zheng-Ping Zhang; Xue-Fang Zhang; Hui Li; Tuan-Jiang Liu; Qin-Peng Zhao; Lin-Hong Huang; Zi-Jun Cao; Li-Min He; Ding-Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.817

8.  Irisin Serum Levels in Metabolic Syndrome Patients Treated with Three Different Diets: A Post-Hoc Analysis from a Randomized Controlled Clinical Trial.

Authors:  Alberto R Osella; Graziana Colaianni; Mario Correale; Pasqua L Pesole; Irene Bruno; Claudia Buongiorno; Valentina Deflorio; Carla M Leone; Silvia Concetta Colucci; Maria Grano; Gianluigi Giannelli
Journal:  Nutrients       Date:  2018-06-28       Impact factor: 5.717

Review 9.  Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Chrysoula Boutari; Nikolaos Perakakis; Christos Socrates Mantzoros
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03

10.  Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Qiang Liu; Xuemei Li; Ji-Zong Zhao; Xianwei Zeng
Journal:  J Neuroinflammation       Date:  2018-05-02       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.